Cargando…

Gulf CARE: Heart failure in the Middle East

Detalles Bibliográficos
Autor principal:	Hassan, Mohamed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bloomsbury Qatar Foundation Journals 2015
Materias:	Lessons from the Trials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4625206/ https://www.ncbi.nlm.nih.gov/pubmed/26566528 http://dx.doi.org/10.5339/gcsp.2015.34

Ejemplares similares

PARADIGM-HF: Have we achieved a new paradigm in the treatment of heart failure?
por: Bonow, Robert O., et al.
Publicado: (2014)

The EMPEROR-Reduced trial: SGLT2 inhibitors for heart failure get more support
por: Wagdy, Kerolos
Publicado: (2020)

EMPEROR-Preserved: SGLT2 inhibitors breakthrough in the management of heart failure with preserved ejection fraction
por: Wagdy, Kerolos, et al.
Publicado: (2021)

Clinical trials of bone marrow derived cells for ischemic heart failure. Time to move on? TIME, SWISS-AMI, CELLWAVE, POSEIDON and C-CURE
por: Raynaud, Christophe M., et al.
Publicado: (2013)

Lessons from a pre-specified meta-analysis of sodium-glucose cotransporter-2 (SGLT2) inhibitors in heart failure: Time for new clinical recommendations
por: Kotit, Susy
Publicado: (2023)

INVICTUS: Vitamin K antagonists remain the standard of care for rheumatic heart disease-associated atrial fibrillation
por: Kotit, Susy
Publicado: (2023)

STABILITY and SOLID-TIMI 52: Lipoprotein associated phospholipase A(2) (Lp-PLA(2)) as a biomarker or risk factor for cardiovascular diseases
por: Hassan, Mohamed
Publicado: (2015)

OSLER and ODYSSEY LONG TERM: PCSK9 inhibitors on the right track of reducing cardiovascular events
por: Hassan, Mohamed
Publicado: (2015)

HPS2-THRIVE, AIM-HIGH and dal-OUTCOMES: HDL-cholesterol under attack
por: Hassan, Mohamed
Publicado: (2014)

APOC3: Triglycerides do matter
por: Hassan, Mohamed
Publicado: (2014)

Niemann-Pick C1-Like 1 protein: Another target for treatment of dyslipidemia? Evidence from the Myocardial Infarction Genetic Consortium and IMPROVE-IT trials
por: Hassan, Mohamed
Publicado: (2014)

FOURIER & PCSK9 RNAi: Towards enhancing durability and efficacy of PCSK9 inhibitors
por: Hassan, Mohamed
Publicado: (2017)

CANTOS: A breakthrough that proves the inflammatory hypothesis of atherosclerosis
por: Hassan, Mohamed
Publicado: (2018)

Towards tailoring blood pressure control in HFpEF: Lessons from OPTIMIZE-HF
por: Hassan, Mohamed
Publicado: (2019)

GAUSS-2, RUTHERFORD-2, LAPLACE-2, DESCARTES, and TESLA Part B: PCSK9 inhibitors gain momentum
por: Hassan, Mohamed, et al.
Publicado: (2014)

CANHEART: Is HDL cholesterol a cardiovascular specific risk factor?
por: Hassan, Mohamed, et al.
Publicado: (2016)

NEAT HFpEF: Organic nitrates fail to deliver
por: Wagdy, Kerolos, et al.
Publicado: (2016)

ASGR1 - a new target for lowering non-HDL cholesterol
por: Hassan, Mohamed, et al.
Publicado: (2016)

The Copenhagen City Heart Study (Østerbroundersøgelsen)
por: Aguib, Yasmine, et al.
Publicado: (2015)

The Dallas Heart Study using the probability sample technique for ethnicity and cardiovascular health differences
por: Al Suwaidi, Jassim
Publicado: (2015)

Dietary patterns and their association with acute coronary heart disease: Lessons from the REGARDS Study
por: Al Suwaidi, Jassim
Publicado: (2015)

Hope for primary cardiovascular prevention with the HOPE (Heart Outcomes Prevention Evaluation)-3 trial findings
por: Suwaidi, Jassim Al
Publicado: (2016)

Is there a role for genetic risk assessment in the treatment of dyslipidemia in primary and secondary prevention of coronary heart disease?
por: Suwaidi, Jassim Al
Publicado: (2015)

RE-ALIGN: First trial of novel oral anticoagulant in patients with mechanical heart valves – The search continues
por: Shazly, Ahmed, et al.
Publicado: (2014)

COMPARE and Pediatric Heart Network Investigator trials: Losartan finally validated in humans with Marfan, but much work remains!
por: Yacoub, Magdi, et al.
Publicado: (2014)

FIRE AND ICE: The quest for the perfect modality in atrial fibrillation ablation
por: Sayed, Mohamed, et al.
Publicado: (2016)

Culprit lesion-only versus complete revascularization in patients with STEMI: Lessons learned from PRAMI, CvLPRIT, and DANAMI-3 PRIMULTI
por: Hassan, Ahmed, et al.
Publicado: (2015)

ROCKET AF adds more concerns about Digoxin safety in patients with atrial fibrillation
por: ElMaghawry, Mohamed
Publicado: (2015)

DECAAF: Emphasizing the importance of MRI in AF ablation
por: ElMaghawry, Mohamed, et al.
Publicado: (2015)

Dronedarone-digoxin interaction in PALLAS: A foxglove connection?
por: ElMaghawry, Mohamed, et al.
Publicado: (2015)

Takotsubo cardiomyopathy: A potentially serious trap (Data from the International Takotsubo Cardiomyopathy Registry)
por: Wagdy, Kerolos, et al.
Publicado: (2015)

REVERSE 5-year follow up: CRT impact persists
por: ElMaghawry, Mohamed, et al.
Publicado: (2014)

STOP-HF: Expanding the role of HF programs into the community
por: ElMaghawry, Mohamed, et al.
Publicado: (2014)

BLOCK-HF: CRT gains new ground
por: ElGuindy, Ahmed M., et al.
Publicado: (2013)

TASTE: One-year follow-up results
por: Elmahdy, Mahmoud Farouk, et al.
Publicado: (2015)

Bioresorbable polymeric scaffolds for coronary revascularization: Lessons learnt from ABSORB III, ABSORB China, and ABSORB Japan
por: Gogas, Bill D., et al.
Publicado: (2015)

Biocorrodible metals for coronary revascularization: Lessons from PROGRESS-AMS, BIOSOLVE-I, and BIOSOLVE-II
por: Bouchi, Yasir H., et al.
Publicado: (2015)

Transfusion Indication Threshold Reduction (TITRe2) trial: When to transfuse and what to give?
por: Afifi, Ahmed, et al.
Publicado: (2015)

CTS Trials Network: Surgical ablation of atrial fibrillation during mitral valve surgery - many questions unanswered
por: Afifi, Ahmed
Publicado: (2015)

INHERIT (INHibition of the renin angiotensin system in hypertrophic cardiomyopathy and the Effect on hypertrophy—a Randomised Intervention Trial with losartan)
por: Olivotto, Iacopo, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_t22rok70rc24qmiq76l4no799q